HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Section

Deals

M&A, licensing, and major transactions shaping the industry

GHO Capital, CBC Group plan to merge, forming $21B healthcare investment firm
DealsFierceBiotech ↗
London-based Global Healthcare Opportunities and Singapore-based CBC Group announced plans to merge, creating …
May 21, 2026
Parabilis, fresh from inking Regeneron pact, plans IPO to fund tumor drug’s phase 3 push
DealsFierceBiotech ↗
With the ink barely dry on an antibody-drug conjugate-style deal with Regeneron, Parabilis Medicines has now t…
May 20, 2026
Quince Trades Rare Disease Ambition for Pulmonary Pivot in Orphai Merger
DealsBriefing
After a failed A-T trial and cash crunch, Quince merges with Orphai Therapeutics, keeping its Nasdaq listing a…
May 20, 2026
Regeneron pens $2.3B pact with Parabilis to develop new type of ADC-like therapy
DealsFierceBiotech ↗
Regeneron has ponied up $125 million in cash and an equity investment in Parabilis Medicines to join forces on…
May 19, 2026
Biopharma M&A maintains strength even as large deals wane
DealsEndpoints News ↗
Biopharma's deals landscape could hardly be better, as large companies take a multi-pronged approach to withst…
May 15, 2026
Bora Buys MacroGenics’ Biologics Manufacturing Arm in $127.5M Deal
DealsBriefing
Taiwan’s Bora Group is buying MacroGenics’ Maryland CDMO operations, adding a 20,000‑liter biologics capacity …
May 15, 2026
← Newer Page 2 Older →
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.